MANNKIND CORPMNKDEarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
MannKind Corporation is a biopharmaceutical company focusing on the discovery, development, and commercialization of therapeutic products for diseases such as diabetes and pulmonary arterial hypertension. Based in Danbury, Connecticut, the company was founded in February 1991.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 8.30% | 22.3M | — | 2024-01-25 |
| The Vanguard Group | 5.66% | 15.2M | — | 2024-02-13 |
| STATE STREET CORPORATION | 4.80% | 56.4K | — | 2024-01-22 |
Insider Transactions
Net 90d: +$259.0K · buys $259.0K / sells $0Range:
Action:
Role:
| Insider | Role | Action | ||||
|---|---|---|---|---|---|---|
| 2026-03-10 | Michael Castagna | Chief Executive Officer | Buy (open market) | 100.0K | $2.59 | $259.0K |
| 2026-03-01 | Shannon James Samuel | Director | Grant | 12.0K | $3.27 | $39.2K |
| 2026-03-01 | Prentiss Christopher B | Chief Financial Officer | Grant | 5.0K | $3.27 | $16.4K |
| 2026-03-01 | HOOPER ANTHONY C | Director | Grant | 35.0K | $3.27 | $114.5K |
| 2026-03-01 | Michael Castagna | Chief Executive Officer | Grant | 15.3K | $3.27 | $50.0K |
| 2026-03-01 | Tross Stuart A | Chief People & Workpl Officer | Grant | 15.3K | $3.27 | $50.0K |
1–6 of 6